Annals of Oncology 14:1768-1775, 2003
© 2003 European Society for Medical Oncology
Original Paper |
High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience
1 Hospital Son Dureta, Palma de Mallorca; 2 Hospital Clinico Universitario, Salamanca; 3 Hospital Nuestra Señora de Aranzazu, San Sebastian; 4 Hospital 12 de Octubre, Madrid; 5 Hospital de la Santa Creu i Sant Pau, Barcelona; 6 Hospital Clinic i Provincial, Barcelona; 7 Hospital General de Jerez, Jerez de la Frontera; 8 Hospital de la Princesa, Madrid; 9 Institut Catala d’Oncologia, Barcelona; 10 Hospital de la Vall de Hebron, Barcelona; 11 Hospital Ramon y Cajal, Madrid; 12 Clinica Universitaria de Navarra, Pamplona; 13 Hospital Juan Canalejo, La Coruña; 14 Hospital Marques de Valdecilla, Santander, Spain
Received 7 July 2003; accepted 11 August 2003
Background:
T-cell immunophenotype constitutes an unfavorable prognostic factor in aggressive non-Hodgkin’s lymphomas. High-dose chemotherapy with autologous stem-cell rescue (HDC/ASCT) is the best salvage therapy for patients with aggressive B-cell lymphomas. However, results with this therapy in peripheral T-cell lymphoma (PTCL) are not well defined.
Patients and methods:
From January 1990 to December 1999, 115 patients with PTCL underwent HDC/ASCT inside the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL-TAMO) registry. At diagnosis the median age was 41 years and 60% of patients presented with two or three risk factors from the adjusted International Prognostic Index (a-IPI). Thirty-two per cent of patients were transplanted in first complete response (CR), 62% in chemosensitive disease and 5% in refractory disease.
Results:
Eighty-six per cent of the patients attained a CR and 5% a partial response (PR). With a median follow-up of 37 months (range 1–133), overall survival (OS), time-to-treatment failure (TTF) and disease-free survival (DFS) at 5 years was 56%, 51% and 60%, respectively; for the 37 patients transplanted in first CR, OS and DFS at 5 years were 80% and 79%, respectively. Lactase dehydrogenase (LDH), a-IPI and disease status pre-transplant were associated with outcome.
Conclusions:
More than half of patients with chemosensitive disease who were transplanted are expected to be alive at 5 years. We confirm the utility of the pre-transplant IPI system in predicting outcome. Salvage treatment results with HDC/ASCT in PTCL are similar to those found in corresponding aggressive B-cell lymphomas.
Key words: autologous transplantation, GEL-TAMO, peripheral T-cell lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study J. Clin. Oncol., January 1, 2009; 27(1): 106 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Foss Treatment Approaches for Aggressive T-cell Lymphomas ASCO Educational Book, January 1, 2009; 2009(1): 480 - 485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mercadal, J. Briones, B. Xicoy, C. Pedro, L. Escoda, C. Estany, M. Camos, L. Colomo, I. Espinosa, S. Martinez, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma Ann. Onc., May 1, 2008; 19(5): 958 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Shustov and K. J. Savage Does High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation Have a Role in the Primary Treatment of Peripheral T-Cell Lymphomas? Hematology, January 1, 2008; 2008(1): 39 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Horwitz Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 289 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood, October 1, 2007; 110(7): 2316 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rodriguez, E. Conde, A. Gutierrez, J. J. Lahuerta, R. Arranz, A. Sureda, J. Zuazu, A. F. de Sevilla, M. Bendandi, C. Solano, et al. The adjusted International Prognostic Index and {beta}-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma Haematologica, August 1, 2007; 92(8): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Smith, J. W. Sweetenham, L. Rybicki, S. Brown, R. M. Dean, M. Kalaycio, R. Sobecks, S. Andresen, E. His, B. Pohlman, et al. Disappointing Outcomes of Peripheral T Cell Lymphoma after Autologous Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 5428 - 5428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen T-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1255 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Savage Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types) Hematology, January 1, 2005; 2005(1): 267 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. O. Armitage, J. M. Vose, and D. D. Weisenburger Towards understanding the peripheral T-cell lymphomas Ann. Onc., October 1, 2004; 15(10): 1447 - 1449. [Full Text] [PDF]
|
|